These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2861096)

  • 21. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacology of famotidine.
    Smith JL
    Digestion; 1985; 32 Suppl 1():15-23. PubMed ID: 2866132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacology of famotidine: a summary.
    Chremos AN
    J Clin Gastroenterol; 1987; 9 Suppl 2():7-12. PubMed ID: 2887616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function.
    Konishi K; Suzuki H; Hayashi M; Saruta T
    J Antimicrob Chemother; 1993 Mar; 31(3):413-20. PubMed ID: 8486575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.
    Lin JH; Chremos AN; Chiou R; Yeh KC; Williams R
    Br J Clin Pharmacol; 1987 Nov; 24(5):669-72. PubMed ID: 2893637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.
    Gladziwa U; Klotz U
    Clin Pharmacokinet; 1993 Apr; 24(4):319-32. PubMed ID: 8098275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
    Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
    Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacokinetic study of roxatidine acetate in chronic renal failure.
    Lameire N; Rosenkranz B; Maass L; Brockmeier D
    Drugs; 1988; 35 Suppl 3():48-52. PubMed ID: 2905249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
    Lameire N; Rosenkranz B; Brockmeier D
    Scand J Gastroenterol Suppl; 1988; 146():100-10. PubMed ID: 2906455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.
    Halstenson CE; Guay DR; Opsahl JA; Hirata CA; Olanoff LS; Novak E; Ko H; Cathcart KS; Matzke GR
    Antimicrob Agents Chemother; 1990 Apr; 34(4):519-23. PubMed ID: 2344159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of beta-methyldigoxin in subjects with normal and impaired renal function.
    Tsutsumi K; Nakashima H; Tateishi T; Imagawa M; Nakano S
    J Clin Pharmacol; 1993 Feb; 33(2):154-60. PubMed ID: 8440765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.